Selective PPAR modulator
Selective PPAR modulators (SPPARMs) are a class of drugs that selectively modulate the activity of the Peroxisome proliferator-activated receptor (PPAR). PPARs are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes.
Mechanism of Action[edit | edit source]
SPPARMs work by selectively binding to PPARs, which are found in cells throughout the body. Once bound, they can either activate or inhibit the receptor, depending on the specific drug and the specific receptor. This selective binding allows SPPARMs to have specific effects on the body, such as reducing inflammation or improving insulin sensitivity, without causing unwanted side effects.
Types of SPPARMs[edit | edit source]
There are three types of PPARs: PPAR-alpha, PPAR-delta, and PPAR-gamma. Each type of PPAR has a different role in the body, and different SPPARMs are designed to target different types of PPARs.
- PPAR-alpha modulators are primarily used to treat hyperlipidemia, a condition characterized by high levels of fats in the blood.
- PPAR-delta modulators are being investigated for their potential to treat metabolic diseases, such as obesity and type 2 diabetes.
- PPAR-gamma modulators are used to treat type 2 diabetes by improving insulin sensitivity.
Clinical Use[edit | edit source]
SPPARMs have a wide range of potential clinical uses. They are currently used to treat conditions such as type 2 diabetes and hyperlipidemia, and are being investigated for their potential to treat other conditions, such as obesity, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease.
Side Effects[edit | edit source]
As with any drug, SPPARMs can have side effects. These can vary depending on the specific drug and the individual taking it. Common side effects can include headache, nausea, and fatigue. More serious side effects can include liver damage and an increased risk of heart failure.
Future Research[edit | edit source]
Research is ongoing into the potential uses of SPPARMs. This includes investigating their potential to treat conditions such as obesity and NAFLD, as well as their potential to improve cardiovascular health.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
